성인릴게임 ∧ 29.rbh283.top ∧ 바다이야기 릴게임 사이트 추천 및 안내
학보서
0
1
19:03
【3.rbh283.top】
릴게임야마토해저이야기사이트꽁머니사이트오리지날 양귀비
[Shin-Min Joon, Edaily Reporter] On September 23 in the South Korean pharmaceutical and biotechnology stock market, remarkable stock surges were seen in Celltrion, Protina, and Viol. Celltrion’s share price rose on expectations that tariff risk would be alleviated by acquir 농협 이자율 ing a US biologics manufacturing facility from global pharma company Eli Lilly.
Protina’s stock jumped sharply after securing a clinical specimen analysis service contract with a multinatio 중고차대출금리 nal company. Viol which is facing delisting procedures on KOSDAQ hit the daily upper price limit for three consecutive days driven by a dominance of buying amid decreased trading volume.
일반상환학자금대출신청
◇Celltrion Acquires Eli Lilly’s Biologics Facility for 460 Billion Won
According to KG Zeroin’s MP Doctor (formerly MarketPoint), Celltr 적금 연체 ion’s stock closed at won 184,200 up 8.93% from the previous trading day. After falling the day before the share price rebounded buoyed by the announcement of a won 460 billion acquisition of Eli Lill 쇼핑몰창업지원센터 y’s biologics manufacturing plant in Branchburg New Jersey, U.S. The transaction lifted investor expectations of reduced tariff risk.
The facility is a large scale campus on 45,000 pyung (149,000 m²), comprising four buildings: a production facility, a logistics warehouse, a technical support wing, and an operations building. Because Celltrion owns unused land of about 11,000 pyung (36,400 m²) on the site, it has room for expansion, which could allow the company to respond preemptively to rising market demand.
Though the headline purchase price is 460 billion won total investment including initial operating expenses and facility expansion is expected to reach won 1.4 trillion over the long term. Celltrion plans to finance it via borrowing and inject the capital into its U.S. subsidiary Celltrion USA, through a paid in capital increase.
In an online press briefing Celltrion Group Chairman Seo Jung jin said “If the U.S. demands tariffs, investing in the U.S. is the answer.”
He added “To deal with tariff issues, we’ve maintained inventory for two years.” He also said that before its domestic production facility is ready Celltrion will sell products made in the USA under contract manufacturing (CMO) agreements. Negotiations to acquire the New Jersey facility from Eli Lilly began about six months ago.
Though other companies vied for it Celltrion was designated as preferred bidder. The formal contract was finalized on September 20. Half of the production lines in the purchased facility will continue manufacturing Eli Lilly products under contract while the other half will be used for Celltrion’s own products. Full scale production including transfer of operations from Lilly validating Celltrion’s own products, and obtaining necessary re approvals is expected in the second half of next year.
The biotech industry views this move as resolving tariff related uncertainties for Celltrion. In addition to mitigating tariff risk industry observers anticipate that Celltrion’s earnings will improve thanks to expansion of its contract manufacturing business. New revenue from CMO contracts with Eli Lilly is expected. The company plans to increase capacity, targeting a facility size about 1.5 times larger than its Incheon Songdo Plant 2. Accordingly its operating margin is expected to gradually rise.
Chairman Seo also noted “The facility isn’t just manufacturing staff it includes R&D personnel and production technology teams making it a natural opportunity to relocate or integrate U.S. based laboratories.” This he said would strengthen a bilateral research system anchored in Songdo, Korea and New Jersey U.S.
◇Protina Secures Global Contract for Clinical Specimen Analysis Services
Protina’s stock closed at won 43,400 up 29.94% compared to the previous day hitting its daily upper bound. The surge followed the company’s securing of a contract worth about 1.2 billion won to supply clinical specimen analysis services to a multinational U.S. pharmaceutical firm. Established in 2015 as a KAIST faculty startup Protina is a big data protein company whose core competency is analyzing protein protein interactions (PPI).
Protina operates a single molecule protein interaction (SPID) platform called PPI Landscape used to quantify interactions among proteins across various sample types feeding into drug discovery.
By rapidly acquiring large datasets of antigen antibody interaction data the platform helps in developing biobetters or discovering new drug candidates. Understanding the composition of protein complexes and interaction networks more precisely boosts success probabilities in identifying disease targets, developing biomarkers and designing modulators.
Notably Protina has drawn attention through an investment by global investment bank JPMorgan. As of July 10 the Asia Pacific branch of JPMorgan Asset Management held a 2.89% stake. Protina has said that JPMorgan’s favorable evaluation of the business potential of its PPI Landscape platform, even before the stock listing, was a key reason for the investment.
A company official commented “The contract shows that our unique technology has been validated which seems to have positively influenced the stock price.”
◇Viol Approaches KOSDAQ Delisting, Stock Hits Three Day Upper Limit
Viol’s share price rose 29.90% from the previous day to won?27,150, marking its third consecutive day at the daily upper price limit. The surge is attributed to a diminished trading volume creating a situation where buying pressure dominates. Indeed, the trading volume dropped from 882,874 shares on September 21 to just 260,321 shares on this day.
Recently, Viol’s majority shareholder changed. In May VIG Partners acquired 56.9% of Viol’s management rights from DMS for 367.9 billion won. Through a tender offer from June 18 to July 7, VIG Partners increased its shareholding to around 85%, then continued purchasing remaining shares on the open market. To prepare for delisting, VIG Partners formed a special purpose company called Vienna Investment Vehicle in June. On July 9 it disclosed the possibility of a cash?settled comprehensive share exchange. This procedure would force purchase of minority shareholders’ shares in order to delist. Once shareholding exceeds 95%, Viol may directly apply for delisting with the Korea Exchange.
If the share purchase agreement between DMS and VIG Partners concludes successfully on September 29 VIG Partners’ ownership will rise to 96.57%. Delisting generally proceeds via board resolution followed by convening a shareholders’ meeting. If approved via a special resolution, the company applies for delisting with the Korea Exchange. After passing the exchange’s review a period of organized trading for remaining shares is set before final delisting occurs.
Viol a medical device company specializing in cosmetic skin beauty equipment, has consistently posted record revenues and operating profits. Last year it recorded sales of 58.2 billion won and operating profit of 36.1 billion won.
Its operating margin of 62% was among the highest in the industry. The company was first to develop a high frequency cosmetic device using microneedles as small as 300 micrometers (μm).
An official at Viol said “There is no particular new development the reduced trading volume has made the buying side more noticeable.”
신민준 ([email protected])
릴게임야마토해저이야기사이트꽁머니사이트오리지날 양귀비
성인릴게임 ∧ 89.rbh283.top ∧ 바다이야기 릴게임 사이트 추천 및 안내
성인릴게임 ∧ 42.rbh283.top ∧ 바다이야기 릴게임 사이트 추천 및 안내
성인릴게임 ∧ 78.rbh283.top ∧ 바다이야기 릴게임 사이트 추천 및 안내
성인릴게임 ∧ 61.rbh283.top ∧ 바다이야기 릴게임 사이트 추천 및 안내
바로가기 go !! 바로가기 go !!
오션파라다이스7게임 알라딘릴게임 슬롯추천 바다이야기 사이트 한게임바둑이 스핀모바게임랜드 바다이야기 넥슨 모바일야마토 릴게임릴게임갓 100원바다이야기 온라인게임 최신게임 슬롯머신 게임 황금성게임공략방법 스톰게임 온라인빠찡고 바다이야기 꽁머니 온라인 슬롯머신 오션파라다이스 먹튀 바다이야기 환전 릴게임가입머니 일본야마토 씨엔조이 릴게임 황금성 오리지널 릴게임릴게임갓 손오공 릴게임 슬롯 확률 강원랜드 슬롯머신 확률 공개 바다이야기 고래 일본경륜 릴게임환전 바다이야기 apk 백경 게임 인터넷신천지 오션파라 다이스 사이트 양귀비게임설명 황금성배당줄 알슬롯 바다이야기 먹튀 돈 받기 온라인백경게임 신천지릴게임 오션파라다이스7게임 바다이야기 온라인 바둑이라이브 백경게임예시 바다신2다운로드 프라그마틱 홈페이지 바다이야기온라인 바다이야기동영상 뽀빠이릴게임 무료슬롯버프 황금성3 야마토온라인주소 캡틴프라이드게임 슬롯머신무료 손오공 오션파라다이스 다운로드 황금성배당줄 바다이야기환전가능 야마토다운 릴게임꽁머니 바다이야기환전가능 바다 이야기 다운 바다이야기부활 모바일야마토 예시 릴게임 확률 바다이야기무료 릴황금성 오리지날 야마토 바다이야기고래출현 소액 슬롯 추천 슬롯머신 영어로 온라인 릴게임 사이트 야마토5게임다운로드 무료인터넷바다이야기 프라그마틱환수율 바다이야기2 오션파라다이스7게임 파칭코 게임 강시 안전 슬롯사이트 양귀비게임 황금성매장 황금성포커성 해외축구일정 상품권릴게임 릴게임 꽁머니 알라딘온라인릴게임 바다이야기기프트전환 릴게임추천사이트 게임몰 릴게임 바다이야기 온라인 알라딘게임공략법 바다이야기게임동영상 릴게임뽀빠이 무료슬롯머신777 무료 슬롯 메타 무료 슬롯 머신 카지노 게임 황금성게임앱 카카오릴게임 바다이야기기계 오징어릴게임 신천지인터넷게임 온라인슬롯머신 체리게임 사다리게임주소 바다이야기기계 황금성갈갈이 야마토2게임주소 손오공릴게임다운로드 슬롯 게임사 추천 바다이야기 환전 가능 슬롯머신 규칙 무료 슬롯 머신 다운 받기 바다이야기파일 인터넷신천지 바다이야기먹튀신고 온라인 릴게임 손오공 신천지인터넷게임 인터넷 바다이야기 인터넷릴게임 야마토2 릴게임 고전릴게임 릴게임이벤트 This article was released as Pharm Edaily Premium Content on September 24, 2025, at 7:16 AM.[Shin-Min Joon, Edaily Reporter] On September 23 in the South Korean pharmaceutical and biotechnology stock market, remarkable stock surges were seen in Celltrion, Protina, and Viol. Celltrion’s share price rose on expectations that tariff risk would be alleviated by acquir 농협 이자율 ing a US biologics manufacturing facility from global pharma company Eli Lilly.
Protina’s stock jumped sharply after securing a clinical specimen analysis service contract with a multinatio 중고차대출금리 nal company. Viol which is facing delisting procedures on KOSDAQ hit the daily upper price limit for three consecutive days driven by a dominance of buying amid decreased trading volume.
일반상환학자금대출신청
◇Celltrion Acquires Eli Lilly’s Biologics Facility for 460 Billion Won
According to KG Zeroin’s MP Doctor (formerly MarketPoint), Celltr 적금 연체 ion’s stock closed at won 184,200 up 8.93% from the previous trading day. After falling the day before the share price rebounded buoyed by the announcement of a won 460 billion acquisition of Eli Lill 쇼핑몰창업지원센터 y’s biologics manufacturing plant in Branchburg New Jersey, U.S. The transaction lifted investor expectations of reduced tariff risk.
The facility is a large scale campus on 45,000 pyung (149,000 m²), comprising four buildings: a production facility, a logistics warehouse, a technical support wing, and an operations building. Because Celltrion owns unused land of about 11,000 pyung (36,400 m²) on the site, it has room for expansion, which could allow the company to respond preemptively to rising market demand.
Though the headline purchase price is 460 billion won total investment including initial operating expenses and facility expansion is expected to reach won 1.4 trillion over the long term. Celltrion plans to finance it via borrowing and inject the capital into its U.S. subsidiary Celltrion USA, through a paid in capital increase.
In an online press briefing Celltrion Group Chairman Seo Jung jin said “If the U.S. demands tariffs, investing in the U.S. is the answer.”
He added “To deal with tariff issues, we’ve maintained inventory for two years.” He also said that before its domestic production facility is ready Celltrion will sell products made in the USA under contract manufacturing (CMO) agreements. Negotiations to acquire the New Jersey facility from Eli Lilly began about six months ago.
Though other companies vied for it Celltrion was designated as preferred bidder. The formal contract was finalized on September 20. Half of the production lines in the purchased facility will continue manufacturing Eli Lilly products under contract while the other half will be used for Celltrion’s own products. Full scale production including transfer of operations from Lilly validating Celltrion’s own products, and obtaining necessary re approvals is expected in the second half of next year.
The biotech industry views this move as resolving tariff related uncertainties for Celltrion. In addition to mitigating tariff risk industry observers anticipate that Celltrion’s earnings will improve thanks to expansion of its contract manufacturing business. New revenue from CMO contracts with Eli Lilly is expected. The company plans to increase capacity, targeting a facility size about 1.5 times larger than its Incheon Songdo Plant 2. Accordingly its operating margin is expected to gradually rise.
Chairman Seo also noted “The facility isn’t just manufacturing staff it includes R&D personnel and production technology teams making it a natural opportunity to relocate or integrate U.S. based laboratories.” This he said would strengthen a bilateral research system anchored in Songdo, Korea and New Jersey U.S.
◇Protina Secures Global Contract for Clinical Specimen Analysis Services
Protina’s stock closed at won 43,400 up 29.94% compared to the previous day hitting its daily upper bound. The surge followed the company’s securing of a contract worth about 1.2 billion won to supply clinical specimen analysis services to a multinational U.S. pharmaceutical firm. Established in 2015 as a KAIST faculty startup Protina is a big data protein company whose core competency is analyzing protein protein interactions (PPI).
Protina operates a single molecule protein interaction (SPID) platform called PPI Landscape used to quantify interactions among proteins across various sample types feeding into drug discovery.
By rapidly acquiring large datasets of antigen antibody interaction data the platform helps in developing biobetters or discovering new drug candidates. Understanding the composition of protein complexes and interaction networks more precisely boosts success probabilities in identifying disease targets, developing biomarkers and designing modulators.
Notably Protina has drawn attention through an investment by global investment bank JPMorgan. As of July 10 the Asia Pacific branch of JPMorgan Asset Management held a 2.89% stake. Protina has said that JPMorgan’s favorable evaluation of the business potential of its PPI Landscape platform, even before the stock listing, was a key reason for the investment.
A company official commented “The contract shows that our unique technology has been validated which seems to have positively influenced the stock price.”
◇Viol Approaches KOSDAQ Delisting, Stock Hits Three Day Upper Limit
Viol’s share price rose 29.90% from the previous day to won?27,150, marking its third consecutive day at the daily upper price limit. The surge is attributed to a diminished trading volume creating a situation where buying pressure dominates. Indeed, the trading volume dropped from 882,874 shares on September 21 to just 260,321 shares on this day.
Recently, Viol’s majority shareholder changed. In May VIG Partners acquired 56.9% of Viol’s management rights from DMS for 367.9 billion won. Through a tender offer from June 18 to July 7, VIG Partners increased its shareholding to around 85%, then continued purchasing remaining shares on the open market. To prepare for delisting, VIG Partners formed a special purpose company called Vienna Investment Vehicle in June. On July 9 it disclosed the possibility of a cash?settled comprehensive share exchange. This procedure would force purchase of minority shareholders’ shares in order to delist. Once shareholding exceeds 95%, Viol may directly apply for delisting with the Korea Exchange.
If the share purchase agreement between DMS and VIG Partners concludes successfully on September 29 VIG Partners’ ownership will rise to 96.57%. Delisting generally proceeds via board resolution followed by convening a shareholders’ meeting. If approved via a special resolution, the company applies for delisting with the Korea Exchange. After passing the exchange’s review a period of organized trading for remaining shares is set before final delisting occurs.
Viol a medical device company specializing in cosmetic skin beauty equipment, has consistently posted record revenues and operating profits. Last year it recorded sales of 58.2 billion won and operating profit of 36.1 billion won.
Its operating margin of 62% was among the highest in the industry. The company was first to develop a high frequency cosmetic device using microneedles as small as 300 micrometers (μm).
An official at Viol said “There is no particular new development the reduced trading volume has made the buying side more noticeable.”
신민준 ([email protected])